Meeting
2014 ASCO Annual Meeting
A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.
Authors
Vijay Maruti Patil
Tata Memorial Hospital, Mumbai, India
Vijay Maruti Patil , Vanita Noronha , Shripad Dinanath Banavali , Amit Joshi , Sachin Dhumal , Supreeta Arya , S Juvekar , Vamshi Krishna Muddu , Bharatsinha Baburao Bhosale , Pankaj Chaturvedi , Devendra Chaukar , P. S. Pai , Anil D'Cruz , Kumar Prabhash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
2014/01/006359
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 6017)
DOI
10.1200/jco.2014.32.15_suppl.6017
Abstract #
6017
Poster Bd #
32
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
First Author: Signe Friesland
Poster
2013 ASCO Annual Meeting
Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.
First Author: Thomas Kuhnt
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil